Related Experiment Video
Updated: Jul 14, 2026

An Optimized Hemagglutination Inhibition (HI) Assay to Quantify Influenza-specific Antibody Titers
Published on: December 1, 2017
[Immunogenicity of trivalent-inactivated influenza vaccine among children less than 4 years old]
Insights
Two doses of trivalent-inactivated influenza vaccine showed lower immunogenicity in younger children. Pre-vaccination antibody titers and age significantly impacted immune response in children under 4 years old.
Area of Science:
- Pediatric immunology
- Vaccinology
- Virology
Context:
- Influenza remains a significant global health concern, particularly for young children who are more susceptible to severe illness.
- Assessing the immunogenicity of influenza vaccines in pediatric populations is crucial for optimizing vaccination strategies and public health outcomes.
Purpose:
- This study evaluated the immunogenicity of a trivalent-inactivated influenza vaccine in children under 4 years old.
- The research aimed to determine the influence of age and prior vaccination status on the immune response to the vaccine.
Summary:
- 259 children received two doses of trivalent-inactivated influenza vaccine, with serum samples collected pre-vaccination and post-vaccination.
- Hemagglutination inhibition (HI) antibody titers were measured to assess immune response, with geometric mean titers, response proportions, and achievement proportions calculated by age group.
- Analysis revealed that younger children (<1.0 and 1.0-1.9 years) exhibited lower antibody titers compared to older children (2.0-2.9 and 3.0-3.9 years).
- Pre-vaccination antibody titer was a strong predictor of antibody increase, while age significantly affected antibody induction against specific influenza strains (A (H1) and B) after two doses.
Impact:
- The findings indicate that the immunogenicity of the trivalent-inactivated influenza vaccine is significantly influenced by a child's age and their pre-existing antibody levels.
- Two vaccine doses were insufficient to achieve protective antibody levels in a substantial proportion of infants and young children, highlighting potential gaps in current pediatric influenza vaccination schedules.
Abstract:
We studied the immunogenicity of trivalent-inactivated influenza vaccine. Subjects were 259 children under 4 years old who visited six pediatric clinics to undergo influenza vaccination. Age distribution was 64 aged <1.0, 65 aged 1.0-1.9, 64 aged 2.0-2.9, and 66 aged 3.0-3.9 years, including subjects who had been previously vaccinated within the last three years, 0% (0/64) aged <1.0, 26% (17/65) aged 1.0-1.9, 72% (46/64) aged 2.0-2.9, and 77% (51/66) aged 3.0-3.9 years old. Two doses of vaccine were given subcutaneously four weeks apart. Dosage was 0.l mL for children under 1 year old, while for children aged one year or older, dosage was 0.2mL, based on standard Japanese recommendations. To measure hemagglutination inhibition (HI) antibody titer, triplet sera were obtained before vaccination (S0), 4 weeks after the first vaccination (S1), and 4 weeks after the second vaccination (S2). The geometric mean of HI antibody titer, the response proportion (titer rise > or =4-fold), and the achievement proportion (postvaccination titer > or =1 : 40) were calculated by age group. Analysis of variance was used to estimate the independent effect of age and prevaccination titer on antibody increase. The geometric means of HI antibody titer were lower among the two younger age groups than among the two older age groups, regardless of vaccine strain or when blood samples were collected. The achievement proportion after 2 doses of vaccine in the <1.0, 1.0-1.9, 2.0-2.9, 3.0-3.9 year age groups were 38%, 58%, 89%, and 85% against A (HI) ; 52%, 54%, 81%, and 73% against A (H3) ; and 23%, 49%, 67%, and 71% against B. Regarding the analysis of variance, prevaccination titer consistently indicated strong effects on antibody increase, regardless of vaccine strain or combination of paired sera. After two doses of vaccine (S2/S0), significant effects of age on antibody induction were shown against A (H1) and B (p = 0.000 and 0.002). Thus, the immunogenicity of trivalent-inactivated influenza vaccine was strongly influenced by prevaccination titer and age. Even two doses of vaccine did not induce a protective antibody level in about 50 to 80% of subjects among infants aged <1.0 year, and 40 to 50% among children 1.0-1.9 year old.
Related Concept Videos
Vaccinations
Poliomyelitis
Development of Immunocompetence
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
Influenza

